Funding for this research was provided by:
La Ligue Contre le Cancer and the French Ministry of Health
Received: 2 April 2020
Revised: 30 November 2020
Accepted: 10 December 2020
First Online: 21 January 2021
Ethics approval and consent to participate
: This study was conducted in accordance with the Declaration of Helsinki. This prospective, multicentre, open-label, randomised trial (six centres) was approved by the regional ethics board (Comité de Protection des Personnes—Ile de France) and identified as NCT01349842. All patients signed informed consent.
: The data that support the findings of this study are available from Institut Curie, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Institut Curie.
: F.-C.B. and J.-Y.P. report grants and non-financial support from Menarini Silicon Biosystem, during the conduct of the study. M.C. reports personal fees and other from Novartis, during the conduct of the study; other from Sanofi, Servier, Abbvie, Accord and Astra Zeneca; personal fees from Lilly, outside the submitted work. The other authors have no disclosures.
: The trial was funded by grants from La Ligue Contre le Cancer and the French Ministry of Health (PHRC 2009 02-057). The circulating tumour biomarkers laboratory is supported by the Institut Curie SIRIC2 programme (grant INCa-DGOS-INSERM_12554).